-
公开(公告)号:US20200325153A1
公开(公告)日:2020-10-15
申请号:US16872279
申请日:2020-05-11
发明人: Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号: C07D495/16 , C07D495/18 , A61K45/06 , C07D495/22 , C07D491/18 , A61K31/519 , C07D491/22 , A61P35/00 , A61P35/02
摘要: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号:US20190144465A1
公开(公告)日:2019-05-16
申请号:US15998789
申请日:2018-08-15
发明人: Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号: C07D495/16 , A61P35/02
摘要: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
-
公开(公告)号:US09840495B2
公开(公告)日:2017-12-12
申请号:US15106670
申请日:2014-12-19
发明人: Hervé Geneste , Wilfried Hornberger , Charles W. Hutchins , Katja Jantos , Andreas Kling , Loic Laplanche , Marcel Van Gaalen
IPC分类号: A01N43/00 , A61K31/00 , C07D401/14 , C07D401/04 , C07B59/00 , C07D405/14 , C07D491/107
CPC分类号: C07D401/14 , C07B59/002 , C07B2200/05 , C07D401/04 , C07D405/14 , C07D491/107
摘要: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
-
公开(公告)号:US09527811B2
公开(公告)日:2016-12-27
申请号:US14570996
申请日:2014-12-15
发明人: Helmut Mack , Andreas Kling , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号: C07D207/26 , C07D207/28 , C07D401/12 , C07D233/34 , C07D239/10 , C07D207/22 , C07D211/78 , C07D211/76 , C07D233/32 , C07D275/03 , C07D401/06 , C07D405/12 , C07D409/12 , C07D417/12 , C07D213/81
CPC分类号: C07D207/22 , C07D207/26 , C07D207/28 , C07D211/76 , C07D211/78 , C07D213/81 , C07D233/32 , C07D233/34 , C07D239/10 , C07D275/03 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.
-
公开(公告)号:US20220259226A1
公开(公告)日:2022-08-18
申请号:US17660355
申请日:2022-04-22
发明人: Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Jesse Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Yujia Dai , Jane Gong , Roberto Risi , Yiyun Yu , Guidong Zhu
IPC分类号: C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16 , A61K31/519 , C07D491/16 , C07D498/16
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20200010480A1
公开(公告)日:2020-01-09
申请号:US16575114
申请日:2019-09-18
发明人: Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号: C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20190055264A1
公开(公告)日:2019-02-21
申请号:US15998688
申请日:2018-08-15
发明人: Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号: C07D498/18 , C07D495/18 , C07D519/00 , A61P35/00
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20150252017A1
公开(公告)日:2015-09-10
申请号:US14717787
申请日:2015-05-20
发明人: Andreas Kling , Katja Jantos , Helmut Mack , Achim Möller , Wilfried Hornberger , Gisela Backfisch , Yanbin Lao , Marjoleen Nijsen
IPC分类号: C07D401/04
CPC分类号: C07D401/04 , C07D207/28 , C07D401/14 , C07D409/14 , C07D417/14
摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C1-C3-alkyl, C1-C3-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, or phenyl-C1-C3-alkyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.
摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 1 -C 3 - 烷基,C 1 -C 3 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基或苯基 - C 1 -C 3 - 烷基,R 4和R 5彼此独立地是卤素,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。
-
公开(公告)号:US20150065477A1
公开(公告)日:2015-03-05
申请号:US14390381
申请日:2013-03-14
发明人: Andreas Kling , Katja Jantos , Helmut Mack , Achim Möller , Wilfried Hornberger , Gisela Backfisch , Yanbin Lao , Marjoleen Nijsen
IPC分类号: C07D401/14 , C07D491/107 , C07D413/14 , C07D491/048 , C07D401/04 , C07D471/04
CPC分类号: C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107
摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R1, R2 and n have the meanings mentioned in the claims and the description, Y is a radical of the formulae (Y1) or (Y2) where # indicates the point of attachment of Y to the pyridine ring, R3, R4, R5, Ry and m have the meanings mentioned in the claims and the description, A is (CH2)p with p being 1, 2, 3 or 4, where one or two hydrogen atoms may be replaced by a radical R6, where A is attached to the 3- or 4-position of the pyrazole radical and R6 has the meaning mentioned in the claims and the description; A1 is (CH2)q with q being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C1-C4-alkyl; and A2 is (CH2)r with r being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C1-C4-alkyl, provided that that r+q is 2, 3, 4, 5 or 6; their tautomers, the hydrates thereof, the pharmaceutically suitable salts of the carbox-amide compounds (I), the prodrugs of (I) and the pharmaceutically suitable salts of the prodrugs, tautomers or hydrates of (I).
摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式(I)的化合物,其中R 1,R 2和n具有权利要求书和描述中所述的含义,Y是式(Y1)或(Y2)的基团,其中#表示 Y连接到吡啶环,R3,R4,R5,Ry和m具有权利要求书和说明书中所述的含义,A是(CH 2)p,其中p是1,2,3或4,其中一个或两个氢 原子可以被基团R6代替,其中A连接到吡唑基团的3-或4-位,R6具有权利要求书和说明书中提及的含义; A 1是(CH 2)q,其中q是0,1,2或3,其中一个或两个氢原子可以被卤素或C 1 -C 4 - 烷基取代; 并且A 2为(CH 2)r,其中r为0,1,2或3,其中一个或两个氢原子可被卤素或C 1 -C 4 - 烷基取代,条件是该r + q为2,3,4,5 或6; 其互变异构体,其水合物,羧酰胺化合物(I)的药学上合适的盐,(I)的前药和(I)的前药,互变异构体或水合物的药学上合适的盐。
-
公开(公告)号:US20150045394A1
公开(公告)日:2015-02-12
申请号:US14522454
申请日:2014-10-23
发明人: Andreas Kling , Helmut Mack , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号: C07D417/04 , C07D413/04 , C07D401/04
CPC分类号: C07D417/04 , C07D277/30 , C07D401/04 , C07D413/04
摘要: The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds.The carboxamide compounds are compounds of the general formula I in which W—R2 is selected from and R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y1, Y2, Y3 and Y4 are CRy, or one or two of the variables Y1 to Y4 are a nitrogen atom and the remaining variables are CRy, wherein the radicals Ry may be identical or different and have the meanings mentioned in the claims.
摘要翻译: 本发明涉及新的羧酰胺化合物及其作为药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与钙蛋白酶活性升高相关的疾病的用途,以及通过施用有效量的这些羧酰胺化合物中的至少一种来进行治疗和/或预防性治疗的方法。 羧酰胺化合物是其中W-R2选自并且R 1,R 2,R 3a,R 3b,Y 1,Y 2,Y 3,Y 4,X,Q,m,k,Rw和Rw *具有通式I的化合物 权利要求中提及的其互变异构体及其药学上合适的盐。 在这些化合物中,优选其中Y1,Y2,Y3和Y4为CRy,或变量Y1至Y4中的一个或两个为氮原子,剩余的变量为CRy,其中基团Ry可以相同或不同,并且具有 权利要求中提及的含义。
-
-
-
-
-
-
-
-
-